» Articles » PMID: 12103254

Polymorphisms in the Promoter Regions of MMP-2, MMP-3, MMP-9 and MMP-12 Genes As Determinants of Aneurysmal Coronary Artery Disease

Overview
Date 2002 Jul 10
PMID 12103254
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Our hypothesis was that functional polymorphisms in matrix metalloproteinase (MMP) genes may act as susceptibility factors for the development of coronary aneurysms (CAs).

Background: Different forms of remodeling have been described at the level of coronary arteries; CA, reported in 1% to 5% of patients with angiographic evidence of coronary artery disease (CAD), are one of them. Matrix metalloproteinases have been implicated in the pathogenesis of aneurysm development through increased proteolysis of extracellular matrix proteins.

Methods: We screened 3,862 patients who underwent coronary angiography and identified 113 patients with CAD with at least one CA (CA group); these patients were matched with 226 patients with CAD without CA (control group). The -1,306 C/T MMP-2, 5A/6A MMP-3, CA-repeat MMP-9 and -82 A/G MMP-12 polymorphisms were determined.

Results: The MMP-2, MMP-9 and MMP-12 polymorphisms were not associated with CA. By contrast, the 5A/5A genotype of MMP-3 was significantly more frequent in the CA group than in the control group (31% vs. 18%, p = 0.015); similarly, the MMP-3 5A allele was more frequent in the CA group (p = 0.009). Three variables were independently associated with CA: the MMP-3 5A/5A genotype (odds ratio [OR] = 2.23, 95% confidence interval [CI] [1.27 to 3.93]), a previous myocardial infarction (OR = 1.91, 95% CI [1.14 to 3.20]) and a history of aortic aneurysm (OR = 21.06, 95% CI [2.35 to 188]).

Conclusions: The MMP-3 5A allele is associated with the occurrence of CA. Our results suggest that an increased proteolysis in the arterial wall may act as a susceptibility factor for the development of CA in patients with coronary atherosclerosis.

Citing Articles

MINOCA as the result of coronary artery aneurysm thrombosis.

Rokyta O J Int Med Res. 2024; 52(12):3000605241301859.

PMID: 39660402 PMC: 11632892. DOI: 10.1177/03000605241301859.


Coronary Artery Aneurysms: A Clinical Case Report and Literature Review Supporting Therapeutic Choices.

Sannino M, Nicolai M, Infusino F, Giulio L, Usai T, Biscotti G J Clin Med. 2024; 13(18).

PMID: 39336835 PMC: 11432381. DOI: 10.3390/jcm13185348.


Anticoagulant and antiplatelet treatment effects on the incidence of major cardiovascular events in patients with coronary artery ectasia: An updated systematic review.

Amirpour A, Zavar R, Danesh M, Mirbod S, Zaker E, Moslemi F Indian Heart J. 2024; 76(4):247-253.

PMID: 39009077 PMC: 11451351. DOI: 10.1016/j.ihj.2024.07.001.


Giant coronary aneurysm and acute myocardial infarction: clinical case report and literature review.

Pala B, Tocci G, Bruno N, Barbato E, Gabrielli D Clin Res Cardiol. 2024; 113(7):1092-1098.

PMID: 38526602 DOI: 10.1007/s00392-024-02418-1.


Giant Coronary Artery Aneurysms Presenting As Posterior Myocardial Infarction.

Ishaq S, Duhan S, Keisham B, Khalid T, Harfouch B Cureus. 2024; 16(1):e52081.

PMID: 38344548 PMC: 10858436. DOI: 10.7759/cureus.52081.